Therapeutic Area Specialist (TAS)

The Therapeutic Area Specialist (TAS) is a high‑science, field‑based commercial role responsible for driving on‑label clinical demand generation for extracorporeal photopheresis (ECP) across approved indications, currently Cutaneous T‑Cell Lymphoma (CTCL). The TAS activates and sustains appropriate adoption by influencing specialist clinicians, identifying and resolving barriers across the end‑to‑end referral and treatment pathway, and serving as the primary commercial point‑of‑contact for assigned accounts. This role delivers growth through disciplined clinical selling, structured pathway problem‑solving, and cross‑functional coordination—while operating within strict compliance boundaries. All TASs own defined territories and are accountable for commercial execution and growth within their geography. This role is responsible for the Central Territory, ideally, located in the Chicago area ### Responsibilities **Clinical Demand Generation & Adoption (Primary Focus | ~70–85%)** - Drive evidence‑based, on‑label adoption of ECP through compliant, high‑quality clinical engagements. - Identify, segment, and activate referring clinicians, including dermatologists, hematologist‑oncologists, and CTCL specialists. - Lead advanced clinical selling discussions focused on: - Appropriate patient identification and selection - Label‑ and guideline‑aligned positioning - Treatment sequencing and care pathway integration - Addressing misconceptions and clinical objections - Execute peer‑to‑peer education strategies (speaker programs, small group discussions, case‑based forums) in collaboration with Speaker Program operations. - Maintain disciplined pre‑ and post‑program follow‑through to convert awareness into referrals and treatment starts. - Drive measurable improvement in referral‑to‑start conversion and time‑to‑treatment. **Commercial Operations Point‑of‑Contact & Pathway Barrier Removal (~15–30%)** - Serve as the primary commercial “front door” for assigned accounts. - Maintain an end‑to‑end view of each account’s treatment pathway, including: - Active ECP treatment activity - Referral pipelines and pending starts (where compliant and measurable) - Pathway and operational constraints impacting adoption - Identify, prioritize, and drive resolution of pathway barriers, including: - Referral routing and handoffs - Treatment readiness and workflow clarity - Stakeholder alignment across referrers, treating clinicians, and coordinators - Coordinate internal resources to resolve barriers while respecting functional accountability: - Customer Experience (operational coordination) - Clinical Trainers (education and onboarding) - Technical / Device Service (service or capacity constraints) - Medical Affairs / MSLs (non‑promotional scientific exchange) - Document barriers, actions, owners, and outcomes in CRM to enable closed‑loop execution. **Clarifying Boundary:** The TAS is accountable for identifying, prioritizing, and driving resolution of commercial pathway barriers but does not execute technical service work, clinical training, contracting, reimbursement operations, or order‑to‑cash processes. **Territory Leadership & Market Development** - Own and execute a territory business plan aligned with national CTCL strategy and priorities. - Maintain an up‑to‑date map of key influencers, referral networks, and emerging stakeholders. - Provide structured field insights to Sales leadership, Marketing, Medical Affairs, and Field Strategy partners. **Compliance & Ethical Standards** - Engage exclusively in on‑label, FDA‑compliant promotional discussions. - Adhere to all applicable laws, regulations, and company policies, including HIPAA and Anti‑Kickback Statute requirements. - Appropriately route all off‑label or unsolicited scientific inquiries to Medical Affairs or MSL partners. **Success Metrics (Examples)** - Growth in CTCL referrals and new ECP treatment starts - Referral‑to‑start conversion improvement - Pathway barrier identification and closur…